Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Life Sci. 2021 Dec 15;287:120088. doi: 10.1016/j.lfs.2021.120088. Epub 2021 Oct 29.
Over the last decades, our knowledge of the key pathogenic mechanisms of Alzheimer's disease (AD) has dramatically improved. Regarding the limitation of current therapeutic strategies for the treatment of multifactorial diseases, such as AD, to be translated into the clinic, there is a growing trend in research to identify risk factors associated with the onset and progression of AD. Here, we review the current literature with a focus on the relationship between gastrointestinal (GI)/liver diseases during the lifespan and the incidence of AD, and discuss the possible mechanisms underlying the link between the diseases. We also aim to review studies evaluating the possible link between the chronic use of the most common GI medications and the future risk of AD development.
在过去的几十年中，我们对阿尔茨海默病（AD）关键发病机制的认识有了显著提高。鉴于目前针对 AD 等多因素疾病的治疗策略在临床上的局限性，研究人员越来越倾向于确定与 AD 发病和进展相关的风险因素。在这里，我们回顾了目前的文献，重点关注一生中胃肠道（GI）/肝脏疾病与 AD 发病率之间的关系，并讨论了疾病之间可能存在的联系的机制。我们还旨在回顾评估最常见 GI 药物的慢性使用与未来 AD 发展风险之间可能存在联系的研究。
